A Divalent Chikungunya and Zika Nanovaccine with Thermostable Self-Assembly Multivalent Scaffold LS-SUMO.

Autor: Li Q; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China., Zhang J; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China., Deng Q; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China., Liao C; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China., Qian J; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China., Chen Z; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China., Lu J; One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2024 May; Vol. 13 (13), pp. e2303619. Date of Electronic Publication: 2024 Feb 21.
DOI: 10.1002/adhm.202303619
Abstrakt: The convergence strategies of antigenic subunits and synthetic nanoparticle scaffold platform improve the vaccine production efficiency and enhance vaccine-induced immunogenicity. Selecting the appropriate nanoparticle scaffold is crucial to controlling target antigens immunologically. Lumazine synthase (LS) is an attractive candidate for a vaccine display system due to its thermostability, modification tolerance, and morphological plasticity. Here, the first development of a multivalent thermostable scaffold, LS-SUMO (SUMO, small ubiquitin-likemodifier), and a divalent nanovaccine covalently conjugated with Chikungunya virus E2 and Zika virus EDIII antigens, is reported. Compared with antigen monomers, LS-SUMO nanoparticle vaccines elicit a higher humoral response and neutralizing antibodies against both antigen targets in mouse sera. Mice immunized with LS-SUMO conjugates produce CD4 + T cell-mediated Th2-biased responses and promote humoral immunity. Importantly, LS-SUMO conjugates possess equivalent humoral immunogenicity after heat treatment. Taken together, LS-SUMO is a powerful biotargeting nanoplatform with high-yield production, thermal stability and opens a new avenue for multivalent presentation of various antigens.
(© 2024 Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: